Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for Neovascular Glaucoma
NCT02914626Phase 3Unknown
- Start
- Oct 2016
- Primary completion
- Oct 2017
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised trial of ranibizumab in neovascular glaucoma (NVG) (2 arms). Primary endpoint: Intraocular pressure at 6 months. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
neovascular glaucoma (NVG)
Beyond the preview
Go deeper on NCT02914626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914626.